{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 35 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'analysed, if necessary in an unscheduled blood test. Should the results meet the criteria of', 'hepatic injury alert, the procedures described in the DILI checklist (provided in ISF or eDC)', 'should be followed.', '5.2.6.2', 'Adverse event and serious adverse event collection and reporting', 'The investigator shall maintain and keep detailed records of all AEs in their patient files.', 'Collection of AEs', 'The study design is of non-interventional nature regarding study medication and the study is', 'conducted within the conditions of the approved marketing authorisation. Sufficient data', 'from controlled interventional trials are available to support the evidence on the safety and', 'efficacy of the studied BI drug. For this reason the following AE collection and reporting', 'requirements have been defined.', 'The following must be collected by the investigator from signing the informed consent', 'onwards until the end of the study:', '-', 'all Serious Adverse Events (SAEs) (regardless of causality),', '-', 'all Non-serious ADRs', '-', 'and AESIs', 'All SAEs, all non-serious ADRs, and AESIs including those persisting after study completion', 'must be followed up until they are resolved, have been sufficiently characterized, or no', 'further information can be obtained.', 'The investigator carefully assesses whether an AE constitutes an ADR using the information', 'below.', 'Causal relationship of adverse event', 'The definition of an adverse reaction implies at least a reasonable possibility of a causal', 'relationship between a suspected medicinal product and an adverse event. An adverse', 'reaction, in contrast to an adverse event, is characterised by the fact that a causal relationship', 'between a medicinal product and an occurrence is suspected.', 'Medical judgment should be used to determine the relationship, considering all relevant', 'factors, including pattern of reaction, temporal relationship, de-challenge or re-challenge,', 'confounding factors such as concomitant medication, concomitant diseases and relevant', 'history.', 'Arguments that may suggest a reasonable causal relationship could be:', 'The event is consistent with the known pharmacology of the drug', 'The event is known to be caused by or attributed to the drug class.', 'A plausible time to onset of the event relative to the time of drug exposure.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 36 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', 'Evidence that the event is reproducible when the drug is re-introduced', 'No medically sound alternative etiologies that could explain the event (e.g.', 'preexisting or concomitant diseases, or co-medications).', 'The event is typically drug-related and infrequent in the general population not', 'exposed to drugs (e.g. Stevens-Johnson syndrome).', 'An indication of dose-response (i.e. greater effect size if the dose is increased, smaller', 'effect size if dose is diminished).', 'Arguments that may suggest that there is no reasonable possibility of a causal relationship', 'could be:', 'No plausible time to onset of the event relative to the time of drug exposure is evident', '(e.g. pre-treatment cases, diagnosis of cancer or chronic disease within days/weeks of', 'drug administration; an allergic reaction weeks after discontinuation of the drug', 'concerned)', 'Continuation of the event despite the withdrawal of the medication, taking into', 'account the pharmacological properties of the compound (e.g. after 5 half-lives).', 'Of note, this criterion may not be applicable to events whose time course is prolonged', 'despite removing the original trigger.', 'Additional arguments amongst those stated before, like alternative explanation (e.g.', 'situations where other drugs or underlying diseases appear to provide a more likely', 'explanation for the observed event than the drug concerned).', 'Disappearance of the event even though the study drug treatment continues or remains', 'unchanged.', 'Intensity of adverse event', 'The intensity of the AE should be judged based on the following:', 'Mild:', 'Awareness of sign(s) or symptom(s) which is/are easily tolerated', 'Moderate:', 'Enough discomfort to cause interference with usual activity', 'Severe:', 'Incapacitating or causing inability to work or to perform usual activities', 'Pregnancy:', 'In rare cases, pregnancy might occur in a study. Once a subject has been enrolled into the', 'study, after having taken nintedanib, the investigator must report any drug exposure during', 'pregnancy, which occurred in a female subject or in a partner to a male subject to the Sponsor', 'by means of Part A of the Pregnancy Monitoring Form. The outcome of the pregnancy', 'associated with the drug exposure during pregnancy must be followed up and reported by', 'means of Part B of the Pregnancy Monitoring Form.', 'In the absence of a reportable AE, only the Pregnancy Monitoring Form must be completed,', 'otherwise the NIS AE form is to be completed and forwarded as well within the respective', 'timelines.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}